CVKD (32) SXTP (38) GRI (37) ERNA (33) ⌘ Pro Terminal →

Eocene Ltd. (EOCN) — RQD Stock Rating Cockpit

$3.10 -3.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.07

Eocene Ltd. (EOCN) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EOCN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Eocene Ltd. (NASDAQ: EOCN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.10 (-3.73% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, EOCN ranks #664 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EOCN compare to CVKD and SXTP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EOCN carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CVKD (Cadrenal Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and SXTP (60 Degrees Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, EOCN leads on earnings multiple (N/A) while EOCN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EOCN?

▼

Per EOCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595353), Eocene Ltd. generated $0 in revenue, -$10.3M in net income, and -$6.3M in free cash flow against $18.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.07 (-0.86%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EOCN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY EOCN SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.22-11.5% Next Q

Q2 (-2Q)

Grade D$2.85+10.5% Next Q

Q3 (-1Q)

Grade E$3.15-1.6% Next Q

Current

Grade D-$3.10-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EOCN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EOCN currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.55) and Max Pain ($3.26) forces dealer call-delta covering toward $12.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EOCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EOCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

47.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE8% OF RANGE

L: $2$3.10H: $12

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on EOCN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (30)

10/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like EOCN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EOCN)

✓Walkthrough of EOCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EOCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.04%▼ DESCENDING CHANNEL

2026-11-02O $3.20H $3.22L $3.10C $3.10VOL 6.8K

RES: $4.61SUP: $1.94SMA50: $3.55SMA200: $4.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EOCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EOCN Butterfly Map → + Track EOCN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EOCN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EOCN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EOCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EOCN)

Health Care Rank #664 of 1016 ⚔️ CVKD vs EOCN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EOCN vs. CVKD, SXTP, GRI, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eocene Ltd. (EOCN) ranks #664 by composite RQD confidence (36/100, grade D-) and #975 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, EOCN leads on earnings valuation at N/A trailing P/E, while EOCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with EOCN at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EOCN ACTIVE Eocene Ltd.	D-	36/100	—	—	-35.0%	-3.73%	$3.4M	Benchmark Subject
CVKD Cadrenal Therapeutics Inc.	E	32/100	—	—	-35.0%	+4.41%	$3.4M	/cvkd-vs-eocn →
SXTP 60 Degrees Pharmaceuticals Inc.	D-	38/100	—	22.3%	-35.0%	-0.79%	$3.3M	/sxtp-vs-eocn →
GRI GRI Bio Inc.	D-	37/100	—	—	-35.0%	-2.55%	$3.4M	/gri-vs-eocn →
ERNA Ernexa Therapeutics Inc.	E	33/100	—	—	-35.0%	-6.63%	$3.4M	/erna-vs-eocn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001595353

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eocene Ltd. (EOCN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.3M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-7.4% YoY). On the balance sheet, EOCN closed FY2025 with $18.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.3M	-$6.3M	-$6.3M	$18.6M	—
FY2024 (FY)	2024-12-31	$0	-$7.5M	-$5.9M	-$5.9M	$18.5M	—
FY2023 (FY)	2023-12-31	$0	-$6.9M	-$6.1M	-$6.1M	—	—

3. EOCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EOCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EOCN compare to CVKD and SXTP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EOCN?

Where is EOCN trading relative to its 50-day, 200-day, and 52-week technical levels?

EOCN last traded at $3.10 (-3.73% on volume of 3,116 shares), positioning the stock -12.68% below its 50-day simple moving average ($3.55) and -32.17% below its 200-day simple moving average ($4.57). Across its 52-week range of $2.33 to $12.32, EOCN sits at the 7.7% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.71 to $3.49).

EOCN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EOCN stock right now?

Eocene Ltd. (EOCN) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is EOCN's 12-month price target and RQD AI Jury consensus?

EOCN's 12-month base price target is $2.79 (range $2.18 to $12.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EOCN RQD Cockpit EOCN 12M Forecast EOCN Earnings & Move EOCN Dividends & DRIP EOCN Insiders & 13F EOCN Whale Options EOCN Profit Sankey EOCN News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EOCN — Eocene Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EOCN scores 36 out of 100, which maps to a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The Fundamental Cash Engine pillar scores 8 of 20, reflecting ROIC of -35% and an FCF yield of 0%; for a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow relative to the price. The Whale 13F Flow pillar scores 5 of 20 and the Insider Conviction pillar scores 5 of 20, which together point to weak institutional and insider support in the source data. The Macro Regime Fit pillar scores 8 of 20 against a Beta of 1.0 and a sector sensitivity that the source does not further quantify. The Forensic Balance Sheet pillar scores 10 of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Taken together, the pillar profile suggests that upside in this rating framework depends primarily on a reversal in cash generation, which the current data does not show, while the valuation tradeoff is that a $3.4M market capitalization with no reported revenue leaves little measurable earnings base against which to judge price.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$0.0M	$-10.3M	N/A	$-6.3M	$4.0M	N/A
FY 2024	$0.0M	$0.0M	$-7.5M	N/A	$-5.9M	$4.7M	N/A
FY 2023	$0.0M	$0.0M	$-6.9M	N/A	$-6.1M	N/A	N/A

Per the SEC financials, net losses widened from $-6.9M in FY 2023 to $-10.3M in FY 2025, with free cash flow negative in every reported period. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, and Debt/Equity is 0.5; reported cash declined from $4.7M in FY 2024 to $4.0M in FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, one item is listed: a TradingView report titled "Eocene Ltd. Estimates – NASDAQ:EOCN," tagged as a yellow-light "MARKET WIRE" item and published one hour before the data timestamp. The source describes it as covering market action, institutional positioning, and fundamental catalysts, but the item itself does not state any specific catalyst. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Risk watch items in the source data are limited to the negative cash flow and net loss trend noted above.

Open Questions

What is the company's pipeline or product stage, given that no revenue is reported across FY 2023 through FY 2025?
What is the fiscal runway implied by cash of $4.0M against a FY 2025 free cash outflow of $-6.3M?
What drove the 52-week range of $2.33 - $12.32 relative to the current price of 3.22?
What is the composition of the Debt/Equity ratio of 0.5 given that debt is listed as N/A in each period?
Who are the largest holders and insiders, given that the holders section is empty?

EOCN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eocene Ltd. (EOCN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EOCN Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 7h ago

Eocene Ltd. Estimates – NASDAQ:EOCN

TradingView report covering Eocene Ltd. (EOCN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 54d ago

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Yahoo Finance coverage on EOCN stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🟡 MARKET WIRE TD Economics • 3d ago

The Weekly Bottom Line

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5iS3JheUxIbE9wdXkzWk1rUkxjT1p6VTJWeW1uMVpPY1hKYTMtNFF2Qzh1ck5JNTNKVGRSWXlBOWFta2xtZ2tVUTVhT0FlUmpqX1M2UngxLXRZZw?oc=5" target="_blank">The Weekly Bottom L

Read Full Source ↗

🟢 CATALYST Deloitte • 14d ago

Private capital–fueled economic growth might be knocking on India’s doors soon

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPbVNEUF9teW9VSlNOTVBOOXNjbVkybkFnOTVDNkljbWpGTld4Z1BhS243VUhJcHJqMjh3UWJDRkQwYlhTam9fMzQwTTRuejFnMlJrUjNteUVmZE5LeUc4ODVPRHhFYVlQNGU4S3RwX1dKc01XTTB4VTR0STV

Read Full Source ↗

🟡 MARKET WIRE Retail Insider • 7d ago

Retail Insider “Q3 2026 Luxury Report”: Flagship Investment Changes the Store Economics

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxORnJTMFFsYVpfNWw3cHJ0cFZ4a3RuYWxUZVNRZ3QyRXF2dVBpU29OVWR6cHVvUU5OcW1jQzVKbnMzVUdTdEM3Q2lxZFhRNHJJWFptWE1UR2Z4Vi1VTDBtYzM1MVo3RzRfUmZOdm5sY3gzajNrMmsxdWZoU2Z

Read Full Source ↗

🔴 RISK WATCH Traders Union • 13d ago

Capital Economics sees stocks falling further as bond outlook improves

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQNjlLb0pxUlBHYlFGZU1HdUl6dzdJSXc1dHZsYkY0bkIzQ0RLbl9uYTZfUkJSRlZmNEJGcVRlVVJxb0pWbHRjOVZLSFFNN3RYRENpSXEtUjYzVXp4bHNSQW1nOWx5QTZaT19YSUM5eVRkQ1VzdEtXTEtYT0l

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EOCN Bull vs. Bear Conversation Board — What's Your Call at $3.10?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EOCN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.83 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EOCN (D- • RQD 36/100) a Buy at $3.22?

Welcome to the EOCN (Eocene Ltd.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.67 (-17.1%)

Spot @ $3.22

Pump the brakes on EOCN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EOCN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Eocene Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.70 (+14.9%)

Spot @ $3.22

EOCN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EOCN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.22 (52-wk range $2.33 - $12.32), any beat on forward guidance forces shorts and underweight funds to chase.